Your browser doesn't support javascript.
loading
Tislelizumab and radiation therapy in low-risk early-stage extranodal natural killer/T-cell lymphoma, nasal type: a phase II study protocol.
Li, Jia-Ying; Qi, Shu-Nan; Hu, Chen; Liu, Xin; Yang, Yong; Wu, Tao; Zheng, Rong; Feng, Xiao-Li; Ni, Xiao-Guang; Jin, Feng-Yan; Song, Yu-Qin; Liu, Wei-Ping; Zhou, Sheng-Yu; Li, Ye-Xiong.
  • Li JY; Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Qi SN; Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
  • Hu C; Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Liu X; Division of Biostatistics & Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Yang Y; Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Wu T; Fujian Medical University Union Hospital, Fuzhou, China.
  • Zheng R; Department of Radiation Oncology, Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, China.
  • Feng XL; Department of Nuclear Medicine, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Ni XG; Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Jin FY; Department of Endoscopy, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Song YQ; Hematology Department, First Hospital of Jilin University, Changchun, China.
  • Liu WP; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Zhou SY; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
  • Li YX; Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Future Oncol ; 20(5): 245-256, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38018460
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células T / Anticuerpos Monoclonales Humanizados Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células T / Anticuerpos Monoclonales Humanizados Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article